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ABSTRACT
Objectives: Previously, our research group has investigated the effect of alendronate (ALN) and simvastatin (SV) in their minimum inhibitory dose 
(IC50) on oral squamous cell carcinoma cell line where inhibition of angiogenesis has been demonstrated. In the present study, we further investigate 
the effect of the previously calculated IC50 of SV and ALN and their combination on two different types of stem cells to show that the same drug may 
have different effects on different cells. 
Methods: Stem cells were isolated from rat adipose tissue and oral mucosa. After passaging, cells were subjected to Aln, Sv separately as well as 
combined in their half maximal inhibitory concentration (IC50). 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assay was performed 
to evaluate cytotoxicity. After seven days, osteogenic differentiation was evaluated using alizarin stain. Real time polymerase chain reaction  was used 
to evaluate Osteopontin gene expression.
Results: Our results demonstrated that the proposed combination of Aln and Sv in their IC50 enhanced the osteogenic differentiation of both types 
of stem cells.
Conclusion: The combined effect of Aln and Sv may represent a novel pharmacological approach in treating bone metastasis and at the same time 
treating the cancer itself.
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INTRODUCTION
Although the therapeutic utilization of stem cells is emerging 
expeditiously as a regenerative option to treat diverse aggressive and 
fatal diseases such as cancer, until now surgery has been the gold 
standard in treating cancerous tissue. Cancer-treating regimens and 
protocols often resort to chemotherapy with or without radiotherapy as 
an adjuvant to surgery. The sarcomas of bone, especially, present a very 
challenging type of tumors since tumor removal that is often indicated 
is usually followed by bone fracture. Moreover, some sort of resistance 
to chemo/radiotherapy usually develops. Alendronate (ALN), a member 
of bisphosphonates family, is a potent inhibitor of bone resorption 
that has been widely administered in conditions such as malignant 
hypercalcemia, osteolytic bone diseases, and osteoporosis [1]. ALN 
has also been reported to exert a significant and dose-dependent effect 
on osteoblastogenesis of human mesenchymal stem cells (MSCs) [2]. 
Similarly, statins are considered potential therapeutic agents for anti-
osteoporotic treatment. Preclinically, ALNs were demonstrated to play 
an effective and safe therapeutic role when used as an adjuvant agent 
to chemotherapy and/or radiotherapy approaches routinely used in the 
management of head and neck squamous cell carcinoma [3,4]. Recent 
in vitro studies on bone marrow stromal cells, embryonic stem cells, and 
osteoblast-like cells have illustrated the anabolic action of statins exert 
on bone through enhancing bone buildup [5]. It was discovered that 
treatment with statins can stimulate cellular osteogenic differentiation 
by enhancing  Bone Morphogenic protein-2 (BMP-2) mRNA expression 
in addition to increasing trabecular bone volume when orally 
administered to ovariectomized rats. However, controversial results 
still exist regarding the biological effect of statins on bone metabolism 
which may be attributed to the different kinds of statins available 
on the market and different dosages and administration methods 
[6]. Recent studies have shown that statins are capable of inducing 
osteogenic differentiation through increasing cell rigidity in MSCs and 
that combined application with osteoconductive materials may asset 
stem cell-based bone tissue engineering [7]. Our group previously 
demonstrated that combining statins with ALNs synergistically 
resulted in the death of cancerous cells of squamous cell carcinoma 
[8]. In the present study, we set to investigate our hypothesis that the 
combination of those two drugs exhibits dual effect depending on the 
type of cells. Here, we investigate the potential of this combination to 
induce osteogenic differentiation when administered to MSCs from 
the oral mucosa and adipose tissue using real-time polymerase chain 
reaction (RT-PCR), which is a technique used to monitor the progress 
of a PCR reaction in RT while quantifying a relatively small amount 
of osteogenic genes. Furthermore, we assessed the enhancing effect 
of this combination of drugs on cell viability using the colorimetric 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay for assessing cell metabolic activity. MTT enables simple and 
reliable counting of metabolically active cells while indicating their 
viability and proliferation rate. Its main advantages are its rapidity, 
accuracy, and the lack of any radioisotopes [9].
MATERIALS AND METHODS
Materials and reagents
ALN (4-amino-1-hydroxybutylidiene-1, 1-bisphosphonate) preparation: 
Stock solutions of the compounds (10 or 20 mM) were prepared in 
distilled water (pH adjusted to 7.4) and filter-sterilized using a 0.2 µm 
filter. Simvastatin (SV) preparation: Stock solutions of the compound 
were prepared by dissolving the powder in dimethyl sulfoxide not 
exceeding 0.1%.
Stem cell isolation and culture
Stem cells used in this study were isolated from fat tissue excised 
from the inguinal pad of fat of mice as well as from their buccal oral 
mucosa. The minced pieces were collected in sterile, labeled, falcon 
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tube. Enzymatic digestion method was used to isolate stem cells 
from extirpated adipose and oral tissue. Tissues were digested with 
collagenase II (R and D) and were kept in an incubator at 37°C for 
90 min while shaking on a shaker every 15 min. The digestion reaction 
was neutralized by adding complete culture medium supplemented 
with fetal bovine serum. Neutralized cells were centrifuged at 
2300 rpm for 5 min. The pellet was resuspended by adding 1 ml of 
routine culture medium and pipetting several times. Resuspended cells 
were then passed through a 70-µm cell strainer (BD Sciences) before 
plating (counting) to remove debris and ensure making a single cell 
suspension. The cells were resuspended at a density of 10,000 cells/cm2 
in complete culture media containing α-MEM with L-glutamine, (Gibco, 
in vitro gen Life Technologies, USA) supplemented with 10% fetal 
bovine serum (Gibco, in vitro gen Life Technologies, USA), antibiotics 
(penicillin G, 100 U/ml, and streptomycin, 100 μg/ml), and antimycotic 
agent (Fungizone, 0.25 μg/ml) in sterile 25 cm2, polystyrene, filter cap, 
cell-culture plates labeled by cell type and date and incubated in a CO2 
incubator at 37°C in a humidified atmosphere of 5% CO2. Cells were 
observed for proliferation and cell morphology twice weekly using an 
inverted light microscope. The cell culture medium was changed as 
needed (every 3–4 days). Once the cells reached 70–80% confluence, 
they were passaged using trypsin/EDTA solution. Cell cultures from the 
third passage were used for differentiation assessment.
Drug treatment and grouping
Minimum inhibitory dose of SV was 6.534 µmole while that of ALN 
was 30.56 µmole as previously calculated by Abd-el-Fattah et al. [8]. 
Group 1: Adipose MSCs (AMSCs) in complete culture medium which 
served as control; Group 1a: AMSCs+ALN, Group 1b: AMSCs+SV, and 
Group 1c: AMSCs+(ALN+SV combination). Group 2: Oral MSCs which 
served as control; Group 2a: Oral MSCs+ALN, Group 2b: Oral MSCs+SV, 
and Group 2c: Oral MSCs+(ALN+SV combination).
Cell viability assessment
MTT reagent and detergent solution were obtained from TACSTM 
TREVIGEN® 8405 Hegerman Ct. Gaithersburg, supplied ready for use 
according to the manufacturer’s instructions. The MTT reagent was 
added (10 µl per well), and the plate was incubated for 2–4 h to allow 
for intracellular reduction of the soluble yellow MTT to the insoluble 
purple formazan dye. When the purple precipitate was clearly visible 
under the microscope, the detergent reagent was added (100 µl per well) 
to solubilize the formazan dye. The quantity of formazan product as 
measured by the amount of 490 nm absorbance is directly proportional 
to the number of living cells in culture plates. Culture plates were 
left with cover in the dark for 2–4 h at room temperature. The plate 
cover was removed, and the absorbance in each well was measured. 
The optical density values were measured at a range from 490 nm to 
630 nm using an enzyme-linked immunosorbent assay plate reader 
(Dynatech MRX 5000; Dynex, Chantilly, VA).
Alizarin red staining
Alizarin red stain (2 g) and distilled water (100 ml), the two 
constituents were mixed well and the pH was adjusted to 4.1–4.3 with 
10% ammonium hydroxide. On day 7 of culture, the induced cells were 
stained using Alizarin Red stain to identify mineralization. The medium 
was carefully aspirated from each plate to avoid aspirating the cells, 
and then, the cells were washed with PBS. The cells were then fixed 
by incubating on ice-cold 70% ethanol for 1 h at room temperature. 
The alcohol was carefully aspirated and rinsed twice (5–10 min each) 
with distilled water. The water was aspirated, and Alizarin Red solution 
was added to cover the plates (500 µl–1 ml per plate). The plates were 
incubated at room temperature for 30 min. The Alizarin Red solution 
was removed and the plates were washed 4 times with 1 ml distilled 
water. Finally, 1-1.5 ml distilled water was added to each plate to prevent 
the cells from drying. The plates were ready for visual inspection and 
image acquisition. The plates were monitored using inverted phase 
contrast microscope, and digital micrographs were taken.
Osteopontin gene expression by quantitative-RT-PCR
The total RNA was extracted from the cultured cells, and RT-PCR was 
performed to analyze the mRNA level of osteoblastic differentiation 
marker gene; Osteopontin (Forward: 5’AGATGATGGTGCAGAGGAA-3’, 
Reverse: 5’GGTGGTTCTGGCAGGGATTT-3’).
Statistical analysis
The collected data were tabulated using Microsoft Excel 
(Microsoft Office, 2007). Analysis of variance was used to test the 
significance of difference between different groups. Tukey’s test was 
used to test the significance of difference between groups. The level of α 




Following the isolation and culturing procedures, cells were kept 
for one week before they started to attach to the bottom of culture 
dishes. The cells exhibited spindle-like or stellate-shaped appearance 
reflecting the diverse morphology of isolated cells (Fig. 1). Cells 
continued to proliferate and propagate until 70–80% of the dish area 
became covered with cells by day 16 (confluence 70–80%). Following 
confluence, the cells were passed successfully up to the third passage. 
Cells maintained their stellate and spindle-like appearance indicating 
an undifferentiated state in the conventional culture media.
ALN and SV combination inhibited cell viability
In Group1 (adipose-derived MSCs [ASCs]), there was no significant 
difference between cell viability of Groups 1a and b as shown by 
Tukey’s test (Table 1 and Fig. 2). Furthermore, there was no significant 
difference between each group and control group. There was a 
significant difference between Group1c and each of the previous 
groups, indicating that combining ALN and SV inhibited cell viability of 
ASCs. Similarly, Group 2 (oral mucosa MSCs) illustrated the same results 
where there was no significant difference between cell viabilities of 
Fig. 1: Isolated oral mesenchymal stem cells (left) and adipose-
derived mesenchymal stem cells (right) in the third passage at 
70–80% confluence. Cells are showing typical stellate and spindle-
shaped appearance of mesenchymal stem cells (scale bar 50 µm)
Table 1: Tukey’s multiple comparisons test comparing cell viability between different sub-groups of AMSCs as assessed by MTT assay
Adipose Control Aln+adipose cells Sim+adipose Adipose MSCs+simvastatin+Alendronate
Mean±SD 1.416±0.254 1.452±0.236 1.6±0.088 0.7086±0.5761
F 11.04
P < 0.0001*
Adipose Control vs. Tukey’s test (q) 0.2972† 1.535† 5.901*
Aln+adipose cells 1.238† 6.198*
Sim+adipose 7.436*
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(Fig. 3). Furthermore, there was no significant difference between each 
group and the control group. There was a significant difference between 
Group 2c and each of the previous groups, indicating that combining 
ALN and SV inhibited cell viability (Table 2).
SV and ALN combination induced osteogenic differentiation
Alizarin red stain results showed minerals formation and confirmed 
osteogenic differentiation. Cells demonstrated orange-red colorimetric 
changes indicating calcium crystal deposition and successful 
osteogenic differentiation of isolated stem cells (Fig. 4). The osteogenic 
gene expression of Osteopontin revealed a highly significant difference 
between Groups 1c and 1a than from Groups 1 and 1b as shown by 
Tukey’s test (Table 3 and Fig. 5). Furthermore, there was a significant 
difference between Group 1c and each of the previous groups, indicating 
that combining ALN and SV highly enhanced the Osteopontin gene 
expression of ASCs. Similarly, there was a highly significant difference 
between Osteopontin gene expression of Groups 2c and 2a than from 
Groups 2 and 2b as shown by Tukey’s test. Furthermore, there was 
Fig. 2: Histogram illustrating cell viability in AMSCs sub-groups as 
assessed by MTT assay
Fig. 4: Alizarin red stain of oral mesenchymal stem cells (left) and 
adipose derived mesennchymal stem cells (right). Positive results 
are indicated by intense orange red staining of calcific nodules 
(Scale Bar 50µm)
Fig. 3: Histogram showing cell viability in OMSCs sub-groups as 
assessed by MTT assay
Fig. 5: Histogram illustrating Osteopontin gene expression via Rt-
PCR in AMSCs sub-groups
Table 2: Tukey’s multiple comparisons test comparing cell viability between different sub-groups of OMSCs as assessed by MTT assay
Oral Control Aln+Oral cells Sim+Oral cells Oral mucosa MSCs+simvastatin+Alendronate
Mean±SD 1.252±0.231 1.632±0.322 1.531±0.921 0.2628±0.09827
F 12.33
P < 0.0001*
Oral Control vs. Tukey’s test (q) 2.134† 1.567† 5.554 *
Aln+Oral cells 0.5671† 7.688 *
Sim+Oral cells 7.121 *
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Fig. 6: Histogram showing Osteopontin gene expression in OMSCs 
sub-groups
Table 4: Tukey’s multiple comparisons test comparing Osteopontin gene expression via Rt-PCR in different sub-groups of group 2
Control MSCs+Alondronate MSCs+ Simvistatin Alondronate+ Simvistatin
Mean±SD 0.4068±0.2121 1.013±0.4773 0.2631±0.1369 1.978±0.3242
F 73.51
P < 0.0001*
Control vs. Tukey’s test (q) 6.668* 1.581† 17.28*
MSCs+Alendronate 8.249* 10.61*
MSCs+ Simvistatin 18.86*
Table 3: Tukey’s multiple comparisons test comparing Osteopontin gene expression via Rt-PCR in different sub-groups of group 1
Adipose Control Aln+adipose cells Sim+adipose Adipose MSCs+simvastatin+Alendronate
Mean±SD 1.416±0.254 1.452±0.236 1.6±0.088 0.7086±0.5761
F 11.04
P < 0.0001*
Adipose Control vs. Tukey’s test (q) 0.2972† 1.535† 5.901*
Aln+adipose cells 1.238† 6.198*
Sim+adipose 7.436*
a significant difference between Group 2c and each of the previous 
groups, suggesting that combining ALN and SV highly enhanced the 
Osteopontin gene expression of oral MSCs (Table 4 and Fig. 6).
DISCUSSION
In this study, we sought to investigate the potential role of a novel 
combination of SV and ALN in inducing osteogenic differentiation 
of stem cells. Routinely, the used osteogenic media constitutes 
dexamethasone, a corticosteroid derivative that can elicit negative 
effects on healing potential if applied clinically [10]. Previous studies 
and researches have concluded the effect of bisphosphonates on 
treatment of bone resorption. This effect was mediated through the 
inhibition of osteoclastic function [11]. Furthermore, the family of 
Statins has shown an anabolic impact on bone metabolism [12]. In this 
study, we were able to obtain positive expression of osteogenic marker; 
Osteopontin. Also, positive Alizarin Red staining was detected after 7 
days of culture in the proposed combination of SV and ALN and this 
is a relatively short duration compared to the 14 days usually taken 
by the routinely used formulation of osteogenic medium. To the best 
of our knowledge, no previous studies have elucidated the effect of 
simultaneous administration of both agents on bone build up. Our team 
has previously studied the anticarcinogenic effect of this combination 
on oral squamous cell carcinoma [8]. In this study, we further illustrate 
an additional impact of this pharmacological combination. Our novel 
findings shall be meaningful if tested and applied in the context of 
osteosarcomas or bone metastasis. These aggressive cancers occurring 
in bone and osteolytic conditions represent a challenge for surgeons, 
especially when determining the appropriate borders of these tumors. 
By introducing this combination of SV and ALN, the amount of bone 
excised from the bony site surrounding the tumor can be minimized. 
Combining both drugs shall exhibit a dual impact through acting as 
anti-carcinogenic agent useful in destroying any cancer cells left in the 
field while inducing osteogenic differentiation of stem cells normally 
present. In the head-and-neck cancer involving bony structures, the 
postsurgical use of obturators was part of the treatment regimen which 
caused additional psychological load for many patients. We present a 
substitute to these regimens by a combination that may remove hidden 
cancer cells and, at the same time, help to restore lost bone. To the best 
of our knowledge, the presented study is the only in vitro study that 
examined this combination of drugs; further studies are recommended 
to validate these results and test the efficacy in vivo.
CONCLUSION
The combined effect of ALN and SV may represent a novel pharmacological 
approach in treating bone metastasis and, at the same time, treating cancer 
itself. The synergistic cytotoxic effect previously described by our team 
should be taken into consideration. In the future, this pharmacological 
combination may provide a novel treatment modality for bone tissue 
regeneration applications.
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